Search Results

Prucalopride 25 mg  | 100.00%

TargetMol

Prucalopride is a selective, high-affinity 5-HT4A/4B receptor agonist (Ki: 2.5/8 nM). It has >290-fold selectivity for 5-HT4A/4B receptor than other 5-HT receptor subtypes.

More Information Supplier Page

Prucalopride 200 mg  | 100.00%

TargetMol

Prucalopride is a selective, high-affinity 5-HT4A/4B receptor agonist (Ki: 2.5/8 nM). It has >290-fold selectivity for 5-HT4A/4B receptor than other 5-HT receptor subtypes.

More Information Supplier Page

Cabozantinib 100 mg  | 99.59%

TargetMol

Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).

More Information Supplier Page

Cabozantinib 200 mg  | 99.59%

TargetMol

Cabozantinib (XL184) is a potent pan-tyrosine kinases inhibitor that inhibits VEGFR2, c-Met, Kit, Axl, and Flt3 (IC50s: 0.035, 1.3, 4.6, 7 and 11.3 nM).

More Information Supplier Page

Ivacaftor 25 mg  | 98.00%

TargetMol

Ivacaftor (VX-770) is a potentiator of CFTR targeting G551D-CFTR (EC50: 100 nM) and F508del-CFTR (EC50: 25 nM) in Fisher rat thyroid cells, respectively.

More Information Supplier Page

Norgestrel 200 mg  | 99.79%

TargetMol

Norgestrel is a synthetic progestin commonly used alone or in combination with an estrogen for contraception. Norgestrel suppresses the secretion of luteinizing and follicle-stimulating hormones (LH and FSH), thickens cervical mucus, and slows the transit of ova through the fallopian tubes.

More Information Supplier Page

Spebrutinib 2 mg  | 97.14%

TargetMol

Spebrutinib is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.

More Information Supplier Page

Spebrutinib 25 mg  | 97.14%

TargetMol

Spebrutinib is an orally bioavailable, selective inhibitor of Bruton’s agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.

More Information Supplier Page